Skip to main content Skip to search

Tumor Microenvironment and Immunotherapy

Description

Our research group is strongly focused on clinical application. The group conducts translational studies using a reverse design approach, aiming to develop new biomarkers and rational, personalized therapeutic strategies for lung cancer patients.

PRIORITY RESEARCH LINES:

  • Discover and validate new mechanisms of sensitivity and resistance to immunotherapy and targeted therapies in lung cancer.

  • Identify new therapeutic targets for lung cancer patients.

  • Develop robust and clinically scalable predictive biomarkers.

  • Design and conduct early-phase (Phase I–II) and late-phase (Phase III) clinical trials with novel immunotherapies and targeted therapies for lung cancer patients.

i+12 english
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

You can also learn more about our Cookie policy and Data protection policy.